Clinical and Translational Allergy is one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology.
Aims and scope
Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience.
Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
Open access publishing enables free access to all content ensuring a wide dissemination of articles; the electronic format and expert peer review allows for very rapid publication. Clinical and Translational Allergy is an international journal reaching out far beyond the borders of Europe, and invites clinicians and researchers from all countries of the world to contribute.
Sign up to receive article alerts
Clinical and Translational Allergy is published continuously online-only and so we encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.
A key component of CTA's collaboration with EAACI Junior Members is to publish webcasted interviews and podcasts where the leading authors from recently published CTA articles are interviewed. The purpose of this initiative is to promote the article, give JMs the opportunity to meet senior authors personally and to discuss with them about details of their work.
The videos are also available on the EAACI YouTube channel
Dr. Clive Grattan, Editor in Chief of Clinical and Translational Allergy, talks with Dr. Carmen Riggioni about new targeted treatments for chronic spontaneous urticaria at PAAM 2017.
The article 'Looking forward to new targeted treatments for chronic spontaneous urticaria' is available here.
This interview with Prof Wagenmann on an accelerated dose escalation with a grass pollen allergoid was recorded for CTA during SERIN 2017.
The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organization active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis. EAACI was founded in 1956 in Florence and has become the largest medical association in Europe in the field of allergy and clinical immunology. It includes over 8,000 members from 121 countries, as well as 47 National Allergy Societies.
EAACI's mission is to promote basic and clinical research; to collect, assess and diffuse scientific information; to act as a scientific reference body for other scientific, health and political organisations; to encourage and provide training and continuous education, and to collaborate with patients and lay organisations.
The Academy aims to provide the most efficient platform for scientific communication and education in the field of allergy and immunology, ultimately striving to ease patients' lives.
For more information please visit www.eaaci.org
Quote from the Editors
Dr Clive Grattan, St John’s Institute of Dermatology, London, UK
Dr Jean Bousquet, University of Montpellier, France
Clinical and Translational Allergy is a pioneering initiative to make high quality peer-reviewed research and reviews in allergy and related subjects available to clinicians, scientists and the public in an open-access format. Advances in allergy and immunology are being made in the clinic and in the laboratory at a rapid rate. CTA provides the platform for rapid dissemination of these findings to a wide audience to provide greatest impact and benefit to society.
EAACI focussed meetings
Clinical and Translational Allergy is proud to be the official destination for the publication of abstracts from the EAACI focussed meetings. You can access these supplements here.
An official journal of EAACI
2017 Journal Metrics
45 days to first decision for reviewed manuscripts only
35 days to first decision for all manuscripts
97 days from submission to acceptance
18 days from acceptance to publication
1,703 Altmetric Mentions